1792999-26-8 Usage
Description
NCB-0846, also known as cis-4-[2-(1H-Benzimidazol-6-ylamino)-8-quinazolinyl]oxy]-cyclohexanol, is a small molecule inhibitor that targets the Traf2 and Nck-interacting protein kinase (TNIK). TNIK plays a crucial role in the regulation of the Canonical Wnt/b-catenin signaling pathway, which is involved in maintaining intestinal stem cells and has been implicated in colorectal carcinogenesis.
Used in Pharmaceutical Industry:
NCB-0846 is used as a therapeutic agent for targeting TNIK, which is involved in the Canonical Wnt/b-catenin signaling pathway. Its inhibition can potentially lead to the prevention or treatment of colorectal cancer by modulating the aberrant activation of this pathway.
Used in Cancer Research:
NCB-0846 is used as a research tool for studying the role of TNIK in the Canonical Wnt/b-catenin signaling pathway and its implications in colorectal carcinogenesis. This can help in understanding the molecular mechanisms underlying the development of colorectal cancer and identifying potential therapeutic targets for its treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 1792999-26-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,7,9,2,9,9 and 9 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1792999-26:
(9*1)+(8*7)+(7*9)+(6*2)+(5*9)+(4*9)+(3*9)+(2*2)+(1*6)=258
258 % 10 = 8
So 1792999-26-8 is a valid CAS Registry Number.
1792999-26-8Relevant articles and documents
Novel quinazoline derivative
-
, (2016/10/08)
The present invention provides a quinazoline derivative represented by formula (I) (in the formula, R1 and R2 represent a hydrogen atom, a halogen atom, or a lower alkyl group optionally having a substituent group, Z represents a cycloakyl group having a
